Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine
Elisa de Lazzari(Hospital Clínic de Barcelona), Estebán Martínez(Instituto de Salud Carlos III), Nadia Abdulghani(Hospital Universitari de Santa Maria), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Juan Tiraboschi(Bellvitge University Hospital), Salvador Fernández‐Arroyo(Universidad de Granada), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), José Luís Blanco(Instituto de Salud Carlos III), Eugenia B Negredo(Universitat Autònoma de Barcelona), José M. Gatell(Universitat de Barcelona), Verònica Alba, Joaquim Peraire(Instituto de Salud Carlos III), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud)
Cited by 6
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2008|1k
Treatment for Adult HIV Infection
|JAMA|2004|737